Home Search
cancer - search results
If you're not happy with the results, please do another search
Scientists Develop UV Activated Drilling Nanomolecules Capable Of Delivering Drugs, Destroying Faulty Cells
Imagine tiny rapidly spinning molecules driven by light capable of burrowing through cell linings when activated or even deliver drugs, whichever suits the occasion?
Sounds...
Pfizer, Celgene And Roche Now Most Active Investors In Sector Overthrowing Novartis And GSK
Corporate venturing has become a key component in many companies' quest for growth, and corporate venture firms are a well-established presence on the biotech...
FDA Announces Crackdown On ‘Unscrupulous’ Stem Cell Clinics
FDA Announces Crackdown On 'Unscrupulous' Stem Cell Clinics
Earlier this week, the US Food and Drug Administration indicated that crackdown on dangerous stem cell clinics, while at...
Celgene Throws In An Additional $195 Million To Expand Deal With Forma
Celgene is paying Forma Therapeutics $195 million upfront for the extended relationship, handing Celgene ex-US rights on drug candidates through October 1, 2019. Under the new...
Synthetic “Mini-Organs” Could Be The Future Of Medicine
Synthetic “Mini-Organs” Could Be The Future Of Medicine
Lab grown “mini-organs” or Organoids are not implantable organs as one might perceive, but are used to...
Biotecnika Times – Newsletter 31.08.2017
Planning For a PhD ? Apply For The Gates Cambridge Scholarship Programme - 2018
The Gates Cambridge Scholarship programme was established in October 2000 by...
Gilead Buys Out Kite Pharma’s CAR-T Therapy In An $11.9-Billion Deal
Gilead Buys Out Kite Pharma’s CAR-T Therapy In An $11.9-Billion Deal
California-based biotech, Gilead Sciences, has reached an $11.9bn agreement to acquire Kite Pharma, adding...
Alembic Pharma Sells Its Baddi Formulation Plant To Scott Edil Pharmacia
Alembic Pharma Sells Its Baddi Formulation Plant To Scott Edil Pharmacia
An Indian API maker, Vadodara-based Alembic Pharmaceuticals, has sold off its non-core asset, the...
AstraZeneca Inks $400 Million Deal With Takeda, To Co-Develop Parkinson’s Drug
AstraZeneca Inks $400 Million Deal With Takeda, To Co-Develop Parkinson’s Drug
AstraZeneca, through a parkinson’s drug deal with takeda, could receive upto $400 million from the...
Biotecnika Times – Newsletter 29.08.2017
Young Researcher Fellowship Programme 2017-2018 | Indo-Japanese Joint Project
The Indian National Science Academy(INSA), New Delhi invites applications from outstanding Indian young scientists.............. Read More
Applications Invited...
BioTecNika Times – Newsletter 28.08.2017
Official Notification For JAM - 2018
IITs and IISc are institutions of national importance and are well known, the world over, for quality education in...
Macrophage Pharma Joined By Merck Ventures In Its Extended Series A Funding Round
The venture capital arm of German pharma giant Merck KGaA, Merck Ventures has now joined existing investors syndicate of CRT Pioneer Fund (CPF), Novo Holdings...
Zebrafish Could A Superior Tumour Testing Model , Study Suggests
Zebrafish is a small vertebrate tropical fish that has recently emerged as one of the most useful models for studying human diseases, including cancers....
Biotecnika Times – Newsletter 24.08.2017
Online Applications Now Open for CSIR NET DEC - 2017 Exam
CSIR will hold the Joint CSIR-UGC Test Tentatively on Sunday 17th December, 2017 for...
National Conference on Recent Trends in Genetic Engineering & Biotechnology @ SRM University
National Conference on Recent Trends in Genetic Engineering & Biotechnology
25th & 26th September, 2017
Organized by
Genetic Engineering Association, Department of Genetic Engineering SRM...
